title: Monitoring glucocorticoid therapy: a pharmacokinetic approach.
abstract: Although glucocorticoid therapy is essential for the treatment of severe inflammatory disorders, there is no systematic approach to patient variables that may affect availability of a steroid dose. After the development of a data base of pharmacokinetic parameters, we examined glucocorticoid pharmacokinetics in 54 patients between 2 and 70 years of age using 70 pharmacokinetic studies after administration of intravenous methylprednisolone (n = 25), oral methylprednisolone (n = 15), intravenous prednisolone (n = 18), and oral prednisone (n = 12). Eleven patients had unusually rapid methylprednisolone elimination (clearance, 565 to 837 ml/min/1.73 m2; population mean, [+/- SD] 380 +/- 100 ml/min/1.73 m2) without an identifiable cause. Incomplete absorption of methylprednisolone and prednisone was observed in three patients and one patient, respectively. Evaluation of glucocorticoid pharmacokinetics in children aged 1 year 8 months to 18 years demonstrated a significant inverse correlation (r = 0.88; p less than 0.001) between prednisolone clearance and age. It is therefore important to consider age in the interpretation of pharmacokinetic data. To simplify measurement of prednisolone clearance, a single-dose single-point method was developed. This was based on a highly significant relationship between the 6-hour postdose prednisolone concentration and prednisolone clearance (log prednisolone clearance = 2.66 + [6-hour postdose concentration] [-0.00167]; r2 = 0.96; p less than 0.0001). Evaluation of glucocorticoid pharmacokinetics in the clinical setting can be used to identify abnormalities in absorption, elimination, and patient compliance. This technique can be used to individualize glucocorticoid dosing regimens.
authors.affiliation: Ira J. and Jacqueline, Neimark Laboratory of Clinical Pharmacology in Pediatrics, Department of Pediatrics, National Jewish Center for Immunology and Respiratory Medicine, Denver, Colo.
authors.forename: M R
authors.initials: MR
authors.lastname: Hill
authors.forename: S J
authors.initials: SJ
authors.lastname: Szefler
authors.forename: B D
authors.initials: BD
authors.lastname: Ball
authors.forename: M
authors.initials: M
authors.lastname: Bartoszek
authors.forename: A M
authors.initials: AM
authors.lastname: Brenner
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D001249:Asthma / Q000188:drug therapy* / Q000378:metabolism; D002648:Child; D002675:Child, Preschool; D005938:Glucocorticoids / Q000008:administration & dosage / Q000493:pharmacokinetics*; D006801:Humans; D007275:Injections, Intravenous; D008775:Methylprednisolone / Q000008:administration & dosage / Q000097:blood; D008875:Middle Aged; D008991:Monitoring, Physiologic; D011239:Prednisolone / Q000008:administration & dosage / Q000097:blood; D011446:Prospective Studies
chemical_list: D005938:Glucocorticoids; D011239:Prednisolone; D008775:Methylprednisolone